# US 2011/0236424 A1 · Treating allergy with detoxified e. coli heat-labile enterotoxin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0236424 A1
- Document ID: US20110236424A1
- Status: Published application
- Kind: A1
- Application number: 12/729,649
- Filed: 2010-03-23
- Published: 2011-09-29
- Earliest claimed: 2010-03-23
- Assignees: Development Center for Biotechnology; Dcb-USA LLC
- Inventors: Yu-Shen Hsu; Jiu-Yao Wang
- Web page: https://patentgrep.com/patent/US20110236424A1

## CPC

- A61K 39/35: Allergens
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61P 11/06: Antiasthmatics
- A61P 27/14: Decongestants or antiallergics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/577: {tolerising response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.

## Claims

### Claim 1

A method for treating allergy, comprising administering to a subject in need thereof a detoxified E. coli heat-labile enterotoxin (LT) in an amount effective for inducing an anti-allergic response in the subject, wherein the detoxified LT exhibits substantially reduced toxicity as compared to its wild-type counterpart.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject suffers from or is at risk for asthma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the detoxified LT contains a mutated subunit A.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mutated subunit A contains an amino acid substitution at the position corresponding to position 61 or position 63 in SEQ ID NO:1.

### Claim 5 (depends on 4)

The method of claim 4, wherein the detoxified LT is LTS61K or LTS63K.

### Claim 6 (depends on 1)

The method of claim 1, wherein the detoxified LT is administered mucosally or transcutaneously.

### Claim 7 (depends on 6)

The method of claim 6, wherein the detoxified LT is administered intranasally, or sublingually.

### Claim 8 (depends on 1)

The method of claim 1, wherein the detoxified LT is formulated in a pharmaceutical composition that is free of allergens.

### Claim 9 (depends on 8)

The method of claim 8, wherein the subject suffers from or is at risk for asthma.

### Claim 10 (depends on 8)

The method of claim 8, wherein the detoxified LT contains a mutated subunit A.

### Claim 11 (depends on 9)

The method of claim 9, wherein the mutated subunit A contains an amino acid substitution at the position corresponding to position 61 or position 63 in SEQ ID NO:1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the detoxified LT is LTS61K or LTS63K.

### Claim 13 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition is administered mucosually or transcutaneously.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pharmaceutical composition is administered intranasally or sublingually.

### Claim 15 (depends on 1)

The method of claim 1, wherein the deroxified LT is formulated in a pharmaceutical composition that contains an allergen.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject suffers from or is at risk for asthma.

### Claim 17 (depends on 15)

The method of claim 15, wherein the detoxified LT contains a mutated subunit A.

### Claim 18 (depends on 17)

The method of claim 17, wherein the mutated subunit A contains an amino acid substitution at the position corresponding to position 61 or position 63 in SEQ ID NO:1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the detoxified LT is LTS61K or LTS63K.

### Claim 20 (depends on 15)

The method of claim 15, wherein the pharmaceutical composition is administered mucosally or transcutaneously.

### Claim 21 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition is administered intranasally or sublingually.
